One of the best approaches against cancer is prevention. Inactivation of the p53 or p16
Introduction
Recent progress in cancer research has clarified many of the molecular mechanisms involved in human carcinogenesis (1). However, overall mortality statistics are unlikely to change fundamentally unless cancer prevention is fully implemented (2). One of the best approaches against cancer is prevention. Chemoprevention, which uses pharmacological agents to preclude carcinogenesis, is one way of accomplishing cancer prevention. The success of chemoprevention depends on a mechanical understanding of carcinogenesis at the molecular level. Cancer arises through the accumulation of genetic abnormalities that enhance the growth or survival of developing tumor cells (1). Inactivation of p53 or p16
INK4a is most prevalent in human cancer (3, 4) . From further analysis, p53 and p16
INK4a
have been proven to be the most important molecules possessing tumor-suppressive function (3, 4). In other words, inactivation of these molecules is a critical event in human tumorigenesis.
Importance of inactivation of the p53 and p16

INK4a genes in human carcinogenesis
The tumor-suppressor gene p53 is most frequently mutated in human malignant tumors (3). Furthermore, individuals with germ-line mutations of p53 are susceptible to many types of malignancies including brain cancer, leukemia, sarcomas and breast cancer, and the familial syndrome is called Li-Fraumeni syndrome (5). Mice with p53 gene deletions develop normally but are highly prone to tumor development. Indeed, p53 is not required for normal cell growth, but acts to prevent cell proliferation under circumstances of cellular stresses (6). Hence, expressions of p53 increase following DNA damage, certain oncogenic stimuli, hypoxia and a variety of other cellular stresses. Activation of p53 prevents cell proliferation by inducing either cell-cycle arrest or apoptosis (6). The p53 protein is a sequence-specific DNA-binding transcription factor, and activates the transcription of genes implicated in cell cycle arrest and apoptosis, such as p21 WAF1/Cip1 , Bax, Gadd45, DR5, Siah-1, Noxa, AIP1 and PUMA. In particular, expression of the cyclindependent kinase inhibitor p21 WAF1/Cip1 is transcriptionally activated by p53 and contributes to p53-dependent cell-cycle arrest by converting the retinoblastoma gene (RB) product to the active unphosphorylated form (6).
Inactivation of the p16 INK4a gene, through gene deletions, point mutations or transcriptional silencing by methylation of the promoter is one of the most frequent defects contributing to human oncogenesis (4). Furthermore, p16
INK4a -deficient mice are susceptible to several types of malignancies, and germ-line mutations in humans are associated with familial syndromes involving malignant melanoma and pancreatic cancer (7). p16
INK4a negatively regulates the cyclin D-cyclin dependent kinase (CDK) 4/6 complexes, thereby suppressing phosphorylation of the RB tumor-suppressor gene product and inhibiting G1/S transition. The p16
INK4a homologs, p15 INK4b , p18
INK4c and p19
INK4d
, have recently been identified (4). All of them bind directly to CDK4/6 and are therefore specific inhibitors of the cyclin D-CDKs. The four members, p15
